Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 13Terminated 4Unknown 3Recruiting 3Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Endocrine 2CNS 1

Conditions

Breast Neoplasms 630Prostatic Neoplasms 372Neoplasms 305Carcinoma, Non-Small-Cell Lung 215Lung Neoplasms 204Colorectal Neoplasms 176Multiple Myeloma 143Pancreatic Neoplasms 136Leukemia, Myeloid, Acute 128Neoplasm Metastasis 124Brain Neoplasms 117Melanoma 116Ovarian Neoplasms 101Carcinoma, Hepatocellular 101Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Glioblastoma 99Uterine Cervical Neoplasms 97Head and Neck Neoplasms 94Squamous Cell Carcinoma of Head and Neck 93Colonic Neoplasms 82Stomach Neoplasms 80Recurrence 80Rectal Neoplasms 80Urinary Bladder Neoplasms 77Sarcoma 77Carcinoma, Renal Cell 76Triple Negative Breast Neoplasms 75Lymphoma 71Lymphoma, Non-Hodgkin 67Leukemia, Lymphocytic, Chronic, B-Cell 66

Interventions

pembrolizumab 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Carcinoma, Small Cell × Clear all
NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
157 enrolled 26 charts
CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled
EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡